Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alnylam Pharmaceuticals reports robust 2022 performance and growth opportunities

Alnylam Pharmaceuticals had a strong financial performance in 2022, driven by the success of AMVUTTRA and advancements in ATTR amyloidosis treatments.
While facing challenges such as FDA requests and the need for self-sustainability, the company is poised for growth with projected revenues and pipeline opportunities.
Opportunities lie in market expansion, innovative pipeline programs, and upcoming regulatory milestones, positioning Alnylam for continued success in RNAi therapeutics.

Alnylam Pharmaceuticals posts robust Q1 growth despite FDA challenges

Alnylam Pharmaceuticals reported strong financial performance in Q1 2023, driven by the TTR franchise and key product sales growth. Despite challenges with the FDA's partial clinical hold, the company remains optimistic about pipeline development and addressing unmet patient needs with RNAi therapeutics.

Alnylam Pharmaceuticals excels in Q2, poised for growth and innovation

Alnylam Pharmaceuticals delivered strong financial results, positive clinical data, and strategic partnerships in Q2 2023, positioning itself for continued growth.
While facing challenges such as market competition and regulatory complexities, Alnylam remains focused on innovation, patient care, and commercial success.
The company's emphasis on R&D, market positioning, and leveraging its RNAi platform underscores its commitment to advancing therapies and driving value for stakeholders.

Alnylam Pharmaceuticals reports robust Q3 growth and eyes HELIOS-B opportunities

Alnylam Pharmaceuticals delivered strong financial results in Q3 2023, showcasing growth and innovation in its product portfolio and pipeline. Despite challenges, the company remains focused on long-term strategies and seizing opportunities in the evolving healthcare landscape.

Alnylam Pharmaceuticals excels in 2023, poised for market leadership

Alnylam Pharmaceuticals demonstrated strong financial performance in 2023, with notable achievements in commercial RNAi therapeutics and franchise growth. The company's strategic focus on innovation, study optimization, and market positioning bodes well for future success and market leadership in RNAi therapeutics.

Alnylam Pharmaceuticals reports robust Q1 performance and strategic readiness

Alnylam Pharmaceuticals showcased strong financial performance, strategic focus on patient needs, and readiness for upcoming milestones.
While facing challenges in meeting guidance and ensuring successful launches, the company is well-positioned for growth and innovation.
Opportunities lie in upcoming milestones, secondary endpoint focus, and future catalysts, driving potential value creation and differentiation.

Alnylam Pharmaceuticals excels in Q2 2024, poised for sustained growth

Alnylam Pharmaceuticals demonstrated strong financial performance and clinical advancements in Q2 2024, driven by key revenue growth drivers and pipeline progress.
While facing challenges such as rising expenses, the company's strategic strengths in franchise performance and margin improvement position it well for future opportunities.
With upcoming milestones and increased guidance, Alnylam is poised to capitalize on growth prospects and maintain its position as a leader in rare disease therapeutics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Alnylam (ALNY) receives a positive opinion from the FDA's advisory committee regarding the label expansion of patisiran to treat the cardiomyopathy of transthyretin-mediated amyloidosis.

Alnylam's (ALNY) Onpattro sNDA Gets FDA Advisory Committee Nod

Alnylam stock tumbled Thursday after a split advisory panel recommended the Food and Drug Administration approve its heart disease treatment.

Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer

Alnylam Pharmaceuticals Inc. ALNY, +3.89% shares fell more than 8% premarket on Thursday after advisers to the U.S. Food and Drug Administration on Wednesday weighed the risks and benefits of the company's treatment for a serious heart condition known as ATTR-CM. The FDA advisory committee voted 9 to 3 that the benefits of the treatment, Onpattro, outweigh its risks in patients with ATTR-CM, but the committee's comments suggest that the drug's label may be limited, analysts say.

Alnylam Pharmaceuticals shares fall after FDA advisers weigh in on heart-disease drug

An outside panel of experts to the U.S. Food and Drug Administration on Wednesday backed the expanded use of Alnylam Pharmaceuticals' gene silencing drug to treat a type of heart disease associated with a rare organ-damaging disorder.

U.S. FDA panel backs expanded use of Alnylam's gene silencing drug

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the positive outcome of the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting to discuss the supplemental New Drug Application (sNDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis. The CRDAC voted 9:3.

Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

BridgeBio Pharma Inc

Roche Holding AG

The pharmaceutical industry is one of the most dynamic and innovative sectors in the world. It is constantly developing new drugs and treatments to address various health challenges and improve the quality of life of millions of people.

Buy List Alert: 3 Pharma Stocks with Positive Trial Updates

Alnylam Pharmaceuticals Inc. ALNY, +3.89% said Wednesday its stock will be halted on Nasdaq through the day as a regulatory advisory committee will meet to review its new drug application for a treatment for the Cardiomyopathy of ATTR Amyloidosis. The treatment called onpattro, or patisiran, is approved in the U.S. and Canada for the treatment of the polyneuropathy of hereditary ATTR (hATTR) amyloidosis in adults.

Alnylam Pharmaceuticals' stock to be halted Wednesday as FDA advisory panel reviews treatment for the Cardiomyopathy of ATTR Amyloidosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that NASDAQ has halted trading of the Company's common stock. The U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee is meeting today to review the supplemental New Drug Application for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) a.

Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Alnylam has an upcoming FDA advisory committee meeting on the company's application for Onpattro in ATTR-CM, and I see some risk of a negative committee vote. Onpattro has met or exceeded the efficacy targets established with the FDA, but I expect the AdComm panelists to challenge the validity of those targets. Alnylam released positive top-line data from the KARDIA-1 Phase II study of zilebesiran, and this looks like a contender in the large hypertension market.

Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some Volatility

Alnylam's (ALNY) mid-stage study of zilebesiran in the treatment of hypertension in patients at high cardiovascular risk meets primary and key secondary endpoints.

Alnylam's (ALNY) Zilebesiran Meets Goals in Mid-Stage Study

Alnylam Pharmaceuticals said on Thursday its experimental therapy for hypertension met the main goal in a mid-stage study.

Alnylam hypertension drug meets main goal in mid-stage study

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, met the primary endpoint demonstrating a dose-dependent, clinically significant reduction in 24-hour mean systolic blood pressure (SBP) measured by ambulatory blood pressure monitori.

Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the first-ever recommendations for patient- and family-centred holistic care for people living with hereditary transthyretin-mediated amyloidosis, also known as hATTR or ATTRv*. The recommendations, published in the BMJ Open,1 were developed by an expert panel of patient advocates and healthcare professionals (HCPs), the Primary Consensus Panel, and endorsed by.

First Set of Recommendations Advocating for the Holistic Care of People Living with hATTR Amyloidosis Developed by International Panel of Patient Advocates and Healthcare Professionals

Moderna

Alnylam Pharmaceuticals said on Friday it plans to appeal a ruling by the U.S. District Court for the District of Delaware on two patents asserted against Moderna for the latter's COVID-19 vaccine Spikevax.

Alnylam to appeal ruling on patents related to Moderna's COVID vaccines

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced an update on its ongoing patent infringement litigation. On March 17, 2022, Alnylam initiated litigation in the United States District Court for the District of Delaware against Moderna for patent infringement. To date, in two separate actions against Moderna, Alnylam has sought to recover reasonable compensation for Moderna's infringement of five Alnylam paten.

Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna

Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs.

Alnylam (ALNY) Q2 Loss Wider Than Expected, Revenues Miss

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Christine Lindenboom - Senior Vice President-Investor Relations and Corporate Communication Yvonne Greenstreet - Chief Executive Officer Tolga Tanguler - Chief Commercial Officer Pushkal Garg - Chief Medical Officer and EVP, Development & Medical Affairs Jeff Poulton - Chief Financial Officer Conference Call Participants Michael Ulz - Morgan Stanley David Lebowitz - Citi Paul Matteis - Stifel Ritu Baral - TD Cowen Maury Raycroft - Jefferies Eliana Merle - UBS William Pickering - Bernstein Gena Wang - Barclays Leland Gershell - Oppenheimer Operator Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Q2 2023 Earnings Conference Call.

Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2023 Earnings Call Transcript

The headline numbers for Alnylam (ALNY) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Alnylam (ALNY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $2.21 per share versus the Zacks Consensus Estimate of a loss of $1.72. This compares to loss of $2.29 per share a year ago.

Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights. “The second quarter of 2023 was a very productive one at Alnylam, with commercial execution delivering 43% year-over-year growth in net product revenues, supported by the strong ongoing launch of AMVUTTRA,” said Yvonne Greenstreet, MBChB, Chief.

Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023 at 10:30 am ET at the InterContinental Hotel in Boston. A live audio webcast of the presentation will be available on the Investors section of the Company's website at www.alnylam.com/events. A replay will be available on the Alnyl.

Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference

Alnylam partnered Roche to develop and commercialize zilebesiran for the treatment of hypertension. Alnylam's share price has not benefited as the announcement was followed by the company revealing a very long development timeline for the candidate. The deal does look like a win-win and sweetens the bad news on the timeline side and it should significantly reduce the cost of development for Alnylam.

Alnylam: Zilebesiran Deal With Roche Reveals A Very Long Development Timeline

Alnylam (ALNY) collaborates with Roche to co-develop and co-commercialize RNAi-based therapeutic, zilebesiran, for the treatment of hypertension in patients with high cardiovascular risk.

Alnylam (ALNY) to Co-Develop Hypertension Drug With Roche

Swiss pharmaceutical group Roche said on Monday it had entered into a partnership with U.S. biopharmaceutical company Alnylam to co-develop and co-commercialise zilebesiran, a therapy to treat hypertension in patients with high cardiovascular risk.

Roche enters partnership with Alnylam for hypertension therapy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has entered into a strategic agreement with Roche to develop and commercialize zilebesiran, Alnylam's investigational RNAi therapeutic for the treatment of hypertension, which is currently in Phase 2 of development. The partnership allows for a bold development plan with the goal of disrupting the hypertension treatment paradigm globally while advancing Alny.

Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk

News for Alnylam Pharmaceuticals Stock (ALNY)